ES2164018B1 - USE OF A LITHIUM SALT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF THE INFECTION CAUSED BY THE HUMAN SYNTHETIC RESPIRATORY VIRUS (VRDH) - Google Patents

USE OF A LITHIUM SALT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF THE INFECTION CAUSED BY THE HUMAN SYNTHETIC RESPIRATORY VIRUS (VRDH)

Info

Publication number
ES2164018B1
ES2164018B1 ES200001347A ES200001347A ES2164018B1 ES 2164018 B1 ES2164018 B1 ES 2164018B1 ES 200001347 A ES200001347 A ES 200001347A ES 200001347 A ES200001347 A ES 200001347A ES 2164018 B1 ES2164018 B1 ES 2164018B1
Authority
ES
Spain
Prior art keywords
treatment
infection caused
preparation
protein
lithium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200001347A
Other languages
Spanish (es)
Other versions
ES2164018A1 (en
Inventor
Vico Nieves Maria Villanueva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto de Salud Carlos III
Original Assignee
Instituto de Salud Carlos III
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto de Salud Carlos III filed Critical Instituto de Salud Carlos III
Priority to ES200001347A priority Critical patent/ES2164018B1/en
Publication of ES2164018A1 publication Critical patent/ES2164018A1/en
Application granted granted Critical
Publication of ES2164018B1 publication Critical patent/ES2164018B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Empleo de una sal de litio en la elaboración de un medicamento para el tratamiento de la infección causada por el virus respiratorio sincitial humano (VRSH). Sales de litio, de fórmula general ALi(n), donde A es el anión de la sal, Li es el catión litio, y n es un número entero igual al número de cargas negativas del anión, tienen la capacidad de inhibir o reducir la fosforilación del dominio III de fosforilación de la proteína P de VRSH, que parece ser esencial para la tetramerización de dicha proteína, localizado en el resto de serina situado en la posición 54 de dicha proteína P de VRSH y controlado por la fosfatasa PP2A, al inhibir específicamente a la proteína quinasa GSK-3. Dichas sales de litio son adecuadas para elaborar un medicamento para el tratamiento de la infección causada por VRSH.Use of a lithium salt in the preparation of a medicine for the treatment of infection caused by the human respiratory syncytial virus (RSVH). Lithium salts, of general formula ALi (n), where A is the salt anion, Li is the lithium cation, and n is an integer equal to the number of negative charges of the anion, they have the ability to inhibit or reduce phosphorylation of the III domain of phosphorylation of the VRSH P protein, which appears to be essential for the tetramerization of said protein, located in the serine moiety located at position 54 of said VRSH P protein and controlled by the PP2A phosphatase, by specifically inhibiting to protein kinase GSK-3. Said lithium salts are suitable for making a medicament for the treatment of infection caused by RSV.

ES200001347A 2000-05-26 2000-05-26 USE OF A LITHIUM SALT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF THE INFECTION CAUSED BY THE HUMAN SYNTHETIC RESPIRATORY VIRUS (VRDH) Expired - Fee Related ES2164018B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200001347A ES2164018B1 (en) 2000-05-26 2000-05-26 USE OF A LITHIUM SALT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF THE INFECTION CAUSED BY THE HUMAN SYNTHETIC RESPIRATORY VIRUS (VRDH)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200001347A ES2164018B1 (en) 2000-05-26 2000-05-26 USE OF A LITHIUM SALT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF THE INFECTION CAUSED BY THE HUMAN SYNTHETIC RESPIRATORY VIRUS (VRDH)

Publications (2)

Publication Number Publication Date
ES2164018A1 ES2164018A1 (en) 2002-02-01
ES2164018B1 true ES2164018B1 (en) 2003-06-16

Family

ID=8493689

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200001347A Expired - Fee Related ES2164018B1 (en) 2000-05-26 2000-05-26 USE OF A LITHIUM SALT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF THE INFECTION CAUSED BY THE HUMAN SYNTHETIC RESPIRATORY VIRUS (VRDH)

Country Status (1)

Country Link
ES (1) ES2164018B1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8320203D0 (en) * 1983-07-27 1983-09-01 Horrobin D F Anti-viral compositions
FR2620620B1 (en) * 1987-09-22 1991-04-05 Atlantic Pharma Prod INHIBITOR OR DESTRUCTIVE SUBSTANCE OF AT LEAST ONE SINGLE-CELL LIVING BEING CONTAINING FLUORINE F- AND LITHIUM LI +
ES2008767A6 (en) * 1987-11-13 1989-08-01 Medical Research Int Destruction of intra-and extra-cellular micro-organisms
GB9023701D0 (en) * 1990-10-31 1990-12-12 Efamol Holdings Medical treatment
FR2715301A1 (en) * 1994-01-24 1995-07-28 Aromafarm Ltd Antiviral use of zinc and lithium ascorbate(s)
GB9621990D0 (en) * 1996-10-22 1996-12-18 Scotia Pharma Ltd Use
CZ295765B6 (en) * 1998-07-29 2005-10-12 Apa - Praha, S.R.O. Therapeutical preparation exhibiting virucidal activity

Also Published As

Publication number Publication date
ES2164018A1 (en) 2002-02-01

Similar Documents

Publication Publication Date Title
UY39529A (en) NEW ANTIVIRAL AGENTS DERIVED FROM SPIROPYRROLIDINE
SI2932970T1 (en) Antiviral therapy
BRPI0410477A (en) compound or a pharmaceutically acceptable salt thereof, method for the prophylaxis or treatment of a chiral condition in a mammal, pharmaceutical formulation, combination, use of a compound, and process for preparing a compound
BR112018008397A2 (en) dihydroimidazopyrazinone derivatives useful in cancer treatment
BR0209774A (en) Cdk inhibitor pyrimidines, their preparation and application as a medicament
BR0113496A (en) A compound or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, use thereof, method for producing a cell cycle inhibitory effect (anti-cell proliferation) in a warm-blooded animal, and pharmaceutical composition.
EE02971B1 (en) Use of droloxyfene or its salts in the manufacture of a medicament for the treatment of bone diseases
BR112013032974A2 (en) "1,6-diazabicyclo [3,2,1] -octan-7-one derivatives, their uses, and pharmaceutical compositions".
YU29502A (en) Process for preparing 4"-substituted -9-deoxo-9a-aza-9a-homoerythromycina derivates
BR0012590A (en) Compound, process for its preparation, pharmaceutical formulation, use of a compound, and, methods for treatment or prophylaxis of pain or discomfort, and for treatment or prophylaxis of neuropathic or central pain
BR0214132A (en) Compound, process for the preparation and use of it, pharmaceutical composition, and method for the treatment of human or non-human animal organism to fight bacterial infection
BR112015029401A8 (en) pyrazolo-pyrrolidin-4-one derivatives, their uses, and pharmaceutical composition and combination
AR039978A1 (en) TREATMENT AND PREVENTION OF OSTEOPOROSIS
SE9901573D0 (en) New compounds
AR019496A1 (en) AZALIDAS OF 13 MEMBERS, PHARMACEUTICAL COMPOSITIONS, USE IN THE PREPARATION OF MEDICINES AND PREPARATION OF THE SAME
BR112018070536A2 (en) compound, pharmaceutical composition, combination, use of a compound or a pharmaceutically acceptable salt thereof, and method of treating a disease or condition
BR112018070514A2 (en) compound, pharmaceutical composition, combination, use of a compound or a pharmaceutically acceptable salt thereof, and method of treating a disease or condition
BR0111933A (en) Use of pamic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterized by deposits of amyloid aggregates
ES2164018B1 (en) USE OF A LITHIUM SALT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF THE INFECTION CAUSED BY THE HUMAN SYNTHETIC RESPIRATORY VIRUS (VRDH)
ATE378335T1 (en) CHIRAL FLUOROCHINOLIZINONE ARGININE SALTS
BR0116653A (en) Medicinal product containing a polyamine as active substance
BR112022009563A2 (en) PYROLOTRIAZINE COMPOUNDS ACTING AS A MNK INHIBITOR
BRPI0409217A (en) antimicrobial derivatives and analogues of [3.1.0] bicycloexylphenyloxazolidinone
ES2182504T3 (en) BIFENILSULFONILCIANAMIDAS, PROCEDURE FOR ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT.
ATE143947T1 (en) N-ACYLPYRROLIDINE AND MEDICINAL PRODUCTS FOR THE TREATMENT OR PROPHYLAXIS OF CKK AND GASTRINE-RELATED DISEASES

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020201

Kind code of ref document: A1

Effective date: 20020201

FG2A Definitive protection

Ref document number: 2164018B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807